LGVN
Longeveron Inc.
Key Financials
Gross Profit
$803000
↓ 57.4%
Revenue
$1.2M
↓ 49.9%
Net Income
$-22704000
↓ 42.1%
Operating Income
$-23287000
↓ 40.9%
EPS (Diluted)
$-1.29
↑ 50.8%
Shareholders' Equity
$5.7M
↓ 74.1%
Total Assets
$10.3M
↓ 59.9%
Total Liabilities
$4.6M
↑ 24.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 8/10/2026 | View on SEC |
| 8-K | 7/29/2026 | View on SEC |
| 3 | 7/21/2026 | View on SEC |
| 3 | 7/14/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
| 3 | 7/13/2026 | View on SEC |
| 3 | 7/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LGVN |
| Company Name | Longeveron Inc. |
| CIK | 1721484 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 305-302-7158 |